Jefferies raises Structure Therapeutics stock target on amylin data

Jefferies reiterated a Buy rating and $125 price target on Structure Therapeutics, implying substantial upside from its $45.55 share price, after favorable early ACCG-2671 amylin and 72-week aleniglipron data. The firm said upcoming clinical readouts could move the roughly $3.8 billion market-cap biotech by 20%-30% or more, citing encouraging weight-loss, tolerability and bone-benefit signals. Structure plans a 12-week Phase 2a study of daily and weekly ACCG-2671 dosing, with data expected in H1 2027, while aleniglipron continues in Phase 3 development.

Analysis

GPCR’s valuation is increasingly an option on differentiated oral incretin/amylin positioning rather than near-term revenue. The key commercial hurdle is not demonstrating weight loss in a low-risk population, but proving durable efficacy, discontinuation rates and dose flexibility in obesity against Lilly’s oral pipeline and Novo Nordisk’s established prescriber ecosystem. Until comparative tolerability and persistence are visible, a premium multiple is vulnerable to compression even if early efficacy remains encouraging.

The small-molecule amylin program creates strategic optionality because amylin combinations could address the muscle-loss, plateauing and maintenance concerns emerging around GLP-1s. However, bone-related observations should not be capitalized into valuation without a powered, longer-duration dataset; they are hypothesis-generating rather than a product differentiator. The nearer value inflection is Phase 3 execution for aleniglipron, while the amylin program is a 2027 catalyst and therefore primarily supports M&A/speculative upside today.

Near term, the analyst reiteration itself is unlikely to create durable incremental demand after the stock’s large prior move and broad target dispersion. Over the next 1-3 months, investor focus should shift to enrollment pace, cash burn and any competitor oral-GLP-1 readouts; positive Lilly/Novo oral data may validate the category but also raise the efficacy bar for GPCR. The thesis is falsified by materially higher discontinuation rates, weaker-than-expected Phase 3 weight loss, a cash runway that requires financing before major readouts, or superior oral data from LLY/NVO that narrows GPCR’s differentiation.

Key Decisions for Investors

• Do not chase GPCR on the rating reiteration; build only a starter position over the next 1-3 months on clinical-data or biotech-sector weakness, with sizing appropriate for a binary Phase 3 outcome. Require an underwritten 2:1 upside/downside to the base case rather than relying on published price targets.
• Use a 6-12 month GPCR call spread rather than outright stock if option liquidity and implied volatility permit; this retains exposure to strategic-interest or clinical-update upside while capping capital at risk. Do not implement until verifying open interest, bid/ask spreads and event-implied volatility.
• Monitor LLY and NVO oral-obesity updates as a relative-value trigger: category validation is supportive for GPCR sentiment, but superior efficacy or tolerability would argue for trimming GPCR and owning the scaled incumbents instead.
• Set a diligence alert around quarterly cash burn and trial-enrollment disclosure. Any indication that funding does not extend through the next decisive clinical catalyst removes a key balance-sheet advantage and raises dilution risk, warranting an exit or hedge.